Management commentary

Bipolar II Disorder: Modelling, Measuring and Managing

Volumn , Issue , 2008, Pages 265-268

  Frangou, Sophia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880924350     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544187.027     Document Type: Chapter

References (15)

1. Bauer, M. S. and Mitchner, L. (2004). What is a “mood stabilizer”? An evidence-based response. American Journal of Psychiatry, 161, 3-18.
2. Bowden, C. L., Grunze, H., Mullen, J. et al. (2005). A randomized, double-blind, placebo- controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry, 66, 111-21.
3. Calabrese, J.R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351-60.
4. Colom, F., Vieta, E., Sanchez-Moreno, J. et al. (2005). Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disorders, 7 (Suppl. 5), S32-6.
5. Guo, J. J., Keck, P. E. Jr., Corey-Lisle, P. K. et al. (2006). Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population- based, case-control study. Journal of Clinical Psychiatry, 67, 1055-61.
6. Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261-9.
7. Judd, L. L., Akiskal, H.S., Schettler, P.J. et al. (2005). Psychosocial disability in the course of Bipolar I and II disorders: a prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322-30.
8. Keck, P. E. Jr., McElroy, S. L., Havens, J. R. et al. (2003). Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Comprehensive Psychiatry, 44, 263-9.
9. Kupka, R. W., Luckenbaugh, D. A., Post, R. M. et al. (2005). Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. American Journal of Psychiatry, 162, 1273-80.
10. Nolen, W. A., Luckenbaugh, D. A., Altshuler, L. L. et al. (2004). Correlates of one-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. American Journal of Psychiatry, 161, 1447-54.
11. Perlis, R. H., Baker, R. W., Zarate, C. A. Jr. et al. (2006). Olanzapine versus risperidone in the treatment of manic or mixed states in Bipolar I Disorder: a randomized, double-blind trial. Journal of Clinical Psychiatry, 67, 1747-53.
12. Post, R. M., Denicoff, K. D., Leverich, G. S. et al. (2003). Morbidity in 258 bipolar outpatients followed for one year with daily prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry, 64, 680-90.
13. Schneck, C. D., Miklowitz, D. J., Calabrese, J.R. et al. (2004). Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. American Journal of Psychiatry, 161, 1902-8.
14. Tohen, M., Greil, W., Calabrese, J. R. etal. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry, 162, 1281-90.
15. Tohen, M., Ketter, T. A., Zarate, C. A. etal. (2003). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. American Journal of Psychiatry, 160, 1263-71.